Pyxis Oncology, Inc. (PYXS)
The price, the headline numbers and the latest news, in one place.
Pyxis Oncology, Inc. (PYXS) Stock Price, Analysis & Data
| Bid | 2.88 |
| Market Cap | 324M |
| Revenue (ttm) | 11M |
| Net Income (ttm) | -88.7M |
| 1.34 | |
| -1.4 | |
| n/a | |
| -3.45 | |
| P/B (ttm) | 21.61 |
| P/S (ttm) | 29.39 |
| Earnings Date | Nov 2, 2026 |
| Ask | 4.51 |
| Volume | 2,230,891 |
| Avg. Volume (20D) | 1,222,566 |
| Open | 3.53 |
| Previous Close | 3.56 |
| Day's Range | 3.53 - 4.05 |
| 52-Week Range | 1.03 - 5.55 |
| Analyst | n/a |
| Price Target | 7 (79.95%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells...
Financial Performance
In 2025, Pyxis Oncology's revenue was 13.86M, a decrease of -14.17% compared to the previous year's 16.15M. Earnings were -79.62M, an increase of 2.96%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for PYXS stock is "null". The 12-month stock price forecast is 7, which is upside of 79.95% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with -100.00% YoY decline.
- EPS of -0.4 misses estimates by -0.05, with -33.33% YoY decline.
Analysts project revenue of ... Upgrade
3 months ago · Simply Wall St.
Creative Global Technology Holdings And 2 Other Promising Penny StocksOver the last 7 days, the U.S. market has risen by 2.6%, and in the past year, it has climbed an impressive 26%, with earnings forecasted to grow by 17% annually. In such a robust market environment, ...
